SCHEMBL544043

SCHEMBL544043

O=C1c2ccccc2C(=O)N1CC1CC1c1cccc2nc(C(F)(F)F)cn12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
GRIN1 Q05586 3/20 0.32
GRIN2A Q12879 3/20 0.32
GRIA2 P42262 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
KEAP1 Q14145 2/20 0.32
HSD17B10 Q99714 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
TGFBR1 P36897 1/20 0.31
MMP1 P03956 1/20 0.30
MMP2 P08253 1/20 0.30
MMP3 P08254 1/20 0.30
MMP9 P14780 1/20 0.30
MMP13 P45452 1/20 0.30
KDM4E B2RXH2 2/20 0.30
ALDH1A1 P00352 2/20 0.30
HPGD P15428 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL543423 0.84 RXFP1 (0.42) CYP1A2CYP2C9CYP2C19MEN1KMT2A
SCHEMBL543620 0.79 HTR2C (0.42)
SCHEMBL543418 0.77 MTNR1A (0.39) GRIN1GRIN2A
SCHEMBL543613 0.73 RXFP1 (0.34) CYP1A2CYP2C9CYP2C19MEN1KMT2A
SCHEMBL4743617 0.66 CYP1A2 (0.53) CYP1A2CYP2C9CYP2C19KMT2AHSD17B10
SCHEMBL14697184 0.65 SLC6A2 (0.49) CYP1A2CYP2C9CYP2C19KMT2AHSD17B10
SCHEMBL14697185 0.65 SLC6A2 (0.49) CYP1A2CYP2C9CYP2C19KMT2AHSD17B10
SCHEMBL27415448 0.65 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19MMP1MMP2
SCHEMBL31417275 0.63 GRIN1 (0.39) GRIN1GRIN2AMEN1KMT2AHSD17B10
SCHEMBL20570124 0.62 CYP1A2 (0.41) CYP1A2CYP2C9CYP2C19MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2141150-B1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2013-12-11 EP disclosed
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 US disclosed
EP-2141150-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF MTNR1A, MTNR1B, XDH CYP1A2 74/4885CYP2C9 199/4885CYP2C19 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.